journal
MENU ▼
Read by QxMD icon Read
search

Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics

journal
https://read.qxmd.com/read/30756363/differentiation-between-guillain-barr%C3%A3-syndrome-and-acute-onset-chronic-inflammatory-demyelinating-polyradiculoneuritis-a-prospective-follow-up-study-using-ultrasound-and-neurophysiological-measurements
#1
Alexander Grimm, Hannah Oertl, Eva Auffenberg, Victoria Schubert, Christoph Ruschil, Hubertus Axer, Natalie Winter
Differentiation of Guillain-Barré syndrome (GBS) and acute-onset chronic inflammatory demyelinating polyradiculoneuritis (CIDP) might be intricate in early stages. We compared electrodiagnostics (EDx) and nerve ultrasound (NUS) as tools for early distinction and follow-up. NUS and EDx have been performed at first visitation and after 6 months. The nerve conduction study score (NCSS), the ultrasound pattern sum score (UPSS), and clinical scores were used for comparison. Compared with the 33 GBS patients, the 34 CIDP patients (50% with symptoms < 4 weeks) revealed significant nerve enlargement in ultrasound (p < 0...
February 12, 2019: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/30756362/nucleic-acid-based-therapeutics-for-parkinson-s-disease
#2
REVIEW
Masayuki Nakamori, Eunsung Junn, Hideki Mochizuki, M Maral Mouradian
Parkinson's disease (PD) is a progressive neurodegenerative disorder that is diagnosed largely on clinical grounds due to characteristic motor manifestations that result from the loss of nigrostriatal dopaminergic neurons. While traditional pharmacological approaches to enhance dopamine levels, such as with L-dopa, can be very effective initially, the chronic use of this dopamine precursor is commonly plagued with motor response complications. Additionally, with advancing disease, non-motor manifestations emerge, including psychosis and dementia that compound patient disability...
February 12, 2019: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/30756361/pridopidine-induces-functional-neurorestoration-via-the-sigma-1-receptor-in-a-mouse-model-of-parkinson-s-disease
#3
Veronica Francardo, Michal Geva, Francesco Bez, Quentin Denis, Lilach Steiner, Michael R Hayden, M Angela Cenci
Pridopidine is a small molecule in clinical development for the treatment of Huntington's disease. It was recently found to have high binding affinity to the sigma-1 receptor, a chaperone protein involved in cellular defense mechanisms and neuroplasticity. Here, we have evaluated the neuroprotective and neurorestorative effects of pridopidine in a unilateral 6-hydroxydopamine (6-OHDA) lesion model of parkinsonism in mice. By 5 weeks of daily administration, a low dose of pridopidine (0.3 mg/kg) had significantly improved deficits in forelimb use (cylinder test, stepping test) and abolished the ipsilateral rotational bias typical of hemiparkinsonian animals...
February 12, 2019: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/30725362/a-longitudinal-study-of-the-neurologic-safety-of-acute-baclofen-use-after-spinal-cord-injury
#4
Jacquelyn J Cragg, Bobo Tong, Catherine R Jutzeler, Freda M Warner, Neil Cashman, Fred Geisler, John L K Kramer
The objective of our study was to determine whether treatment with baclofen is neurologically safe with respect to exposure during recovery from spinal cord injury. We performed a secondary longitudinal analysis of a cohort of adult patients with traumatic acute spinal cord injury. Cumulative baclofen dose was computed over the first 4 weeks following injury from concomitant medication information from a completed clinical trial. The main outcome measure was neurologic status, which was assessed over 52 weeks with "marked recovery" defined as the conversion to higher sensory and motor function...
February 6, 2019: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/30680637/anti-inflammatory-and-neuroprotective-effects-of-dipopa-n-n-diisopropyl-2-oxopropanamide-an-ethyl-pyruvate-bioisoster-in-the-postischemic-brain
#5
Hye-Kyung Lee, Ju-Young Park, Hahnbie Lee, Il-Doo Kim, Seung-Woo Kim, Sung-Hwa Yoon, Ja-Kyeong Lee
Ethyl pyruvate (EP) is a simple aliphatic ester of pyruvic acid and has been shown to have protective properties, which have been attributed to its anti-inflammatory, anti-oxidative, and anti-apoptotic functions. In an effort to develop better derivatives of EP, we previously synthesized DEOPA (N,N-diethyl-2-oxopropanamide, a novel isoster of EP) which has greater neuroprotective effects than EP, probably due to its anti-inflammatory and anti-excitotoxic effects. In the present study, we synthesized 3 DEOPA derivatives, in which its diethylamino group was substituted with diisopropylamino, dipropylamino, or diisobutylamino groups...
January 24, 2019: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/30652253/stereoelectroencephalography-versus-subdural-electrodes-for-localization-of-the-epileptogenic-zone-what-is-the-evidence
#6
REVIEW
Joel S Katz, Taylor J Abel
Accurate and safe localization of epileptic foci is the crux of surgical therapy for focal epilepsy. As an initial evaluation, patients with drug-resistant epilepsy often undergo evaluation by noninvasive methods to identify the epileptic focus (i.e., the epileptogenic zone (EZ)). When there is incongruence of noninvasive neuroimaging, electroencephalographic, and clinical data, direct intracranial recordings of the brain are often necessary to delineate the EZ and determine the best course of treatment. Stereoelectroencephalography (SEEG) and subdural electrodes (SDEs) are the 2 most common methods for recording directly from the cortex to delineate the EZ...
January 16, 2019: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/30652252/a-new-era-for-surgical-neurotherapeutics
#7
EDITORIAL
R Mark Richardson, Taylor J Abel
No abstract text is available yet for this article.
January 16, 2019: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/30644073/oligonucleotide-therapeutics-as-a-new-class-of-drugs-for-malignant-brain-tumors-targeting-mrnas-regulatory-rnas-mutations-combinations-and-beyond
#8
REVIEW
Anna M Krichevsky, Erik J Uhlmann
Malignant brain tumors are rapidly progressive and often fatal owing to resistance to therapies and based on their complex biology, heterogeneity, and isolation from systemic circulation. Glioblastoma is the most common and most aggressive primary brain tumor, has high mortality, and affects both children and adults. Despite significant advances in understanding the pathology, multiple clinical trials employing various treatment strategies have failed. With much expanded knowledge of the GBM genome, epigenome, and transcriptome, the field of neuro-oncology is getting closer to achieve breakthrough-targeted molecular therapies...
January 14, 2019: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/30644072/herpes-viruses-alzheimer-s-disease-and-related-dementias-unifying-or-confusing-hypothesis
#9
Avindra Nath
No abstract text is available yet for this article.
January 14, 2019: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/30635869/nucleic-acid-therapies-for-ischemic-stroke
#10
REVIEW
Nils Henninger, Yunis Mayasi
Stroke remains a leading cause of disability and death worldwide despite significant scientific and therapeutic advances. Therefore, there is a critical need to improve stroke prevention and treatment. In this review, we describe several examples that leverage nucleic acid therapeutics to improve stroke care through prevention, acute treatment, and recovery. Aptamer systems are under development to increase the safety and efficacy of antithrombotic and thrombolytic treatment, which represent the mainstay of medical stroke therapy...
January 11, 2019: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/30635868/plasma-periostin-and-delayed-cerebral-ischemia-after-aneurysmal-subarachnoid-hemorrhage
#11
Hideki Kanamaru, Fumihiro Kawakita, Fumi Nakano, Yoichi Miura, Masato Shiba, Ryuta Yasuda, Naoki Toma, Hidenori Suzuki
Delayed cerebral ischemia (DCI) is a serious complication of aneurysmal subarachnoid hemorrhage (SAH). Matricellular protein periostin (POSTN) has been found to be upregulated and linked with early brain injury after experimental SAH. The aim of the present study was to investigate the relationship between plasma POSTN levels and various clinical factors including serum levels of C-reactive protein (CRP), an inflammatory marker, in 109 consecutive SAH patients whose POSTN levels were measured at days 1-12 after aneurysmal obliteration...
January 11, 2019: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/30627958/prostaglandin-a1-inhibits-the-cognitive-decline-of-app-ps1-transgenic-mice-via-ppar%C3%AE-abca1-dependent-cholesterol-efflux-mechanisms
#12
Guo-Biao Xu, Liu-Qing Yang, Pei-Pei Guan, Zhan-You Wang, Pu Wang
Prostaglandins (PGs) are early and key contributors to chronic neurodegenerative diseases. As one important member of classical PGs, PGA1 has been reported to exert potential neuroprotective effects. However, the mechanisms remain unknown. To this end, we are prompted to investigate whether PGA1 is a useful neurological treatment for Alzheimer's disease (AD) or not. Using high-throughput sequencing, we found that PGA1 potentially regulates cholesterol metabolism and lipid transport. Interestingly, we further found that short-term administration of PGA1 decreased the levels of the monomeric and oligomeric β-amyloid protein (oAβ) in a cholesterol-dependent manner...
January 9, 2019: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/30617654/herpes-infections-and-dementia-rebutting-alternative-fact
#13
Richard Lathe, Nian-Sheng Tzeng, Ruth Itzhaki
Recent commentary in Neurotherapeutics by Nath critically addresses the earlier report by Tzeng et al. that aggressive antiviral treatment (AVT) against herpes simplex virus (HSV) was associated with a later decrease in the incidence of Alzheimer's disease (AD). Nath raises issues that we respond to: we point out that (i) the treated group (probably with severe infection) is likely to harbor genetic risk alleles that predispose to both AD and HSV infection-the potential treatment bias cited by Nath would support (rather than challenge) the preventive effect of AVT; (ii) HSV is well known to establish persistent infection in the brain; and (iii) current AVT compounds used to combat herpes viruses are highly specific for this class of viruses...
January 7, 2019: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/30617653/the-potential-for-a-speech-brain-computer-interface-using-chronic-electrocorticography
#14
REVIEW
Qinwan Rabbani, Griffin Milsap, Nathan E Crone
A brain-computer interface (BCI) is a technology that uses neural features to restore or augment the capabilities of its user. A BCI for speech would enable communication in real time via neural correlates of attempted or imagined speech. Such a technology would potentially restore communication and improve quality of life for locked-in patients and other patients with severe communication disorders. There have been many recent developments in neural decoders, neural feature extraction, and brain recording modalities facilitating BCI for the control of prosthetics and in automatic speech recognition (ASR)...
January 7, 2019: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/30607748/toward-electrophysiology-based-intelligent-adaptive-deep-brain-stimulation-for-movement-disorders
#15
REVIEW
Wolf-Julian Neumann, Robert S Turner, Benjamin Blankertz, Tom Mitchell, Andrea A Kühn, R Mark Richardson
Deep brain stimulation (DBS) represents one of the major clinical breakthroughs in the age of translational neuroscience. In 1987, Benabid and colleagues demonstrated that high-frequency stimulation can mimic the effects of ablative neurosurgery in Parkinson's disease (PD), while offering two key advantages to previous procedures: adjustability and reversibility. Deep brain stimulation is now an established therapeutic approach that robustly alleviates symptoms in patients with movement disorders, such as Parkinson's disease, essential tremor, and dystonia, who present with inadequate or adverse responses to medication...
January 3, 2019: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/30607747/genetics-mechanisms-and-therapeutic-progress-in-polyglutamine-spinocerebellar-ataxias
#16
REVIEW
Ronald A M Buijsen, Lodewijk J A Toonen, Sarah L Gardiner, Willeke M C van Roon-Mom
Autosomal dominant cerebellar ataxias (ADCAs) are a group of neurodegenerative disorders characterized by degeneration of the cerebellum and its connections. All ADCAs have progressive ataxia as their main clinical feature, frequently accompanied by dysarthria and oculomotor deficits. The most common spinocerebellar ataxias (SCAs) are 6 polyglutamine (polyQ) SCAs. These diseases are all caused by a CAG repeat expansion in the coding region of a gene. Currently, no curative treatment is available for any of the polyQ SCAs, but increasing knowledge on the genetics and the pathological mechanisms of these polyQ SCAs has provided promising therapeutic targets to potentially slow disease progression...
January 3, 2019: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/30560481/spatial-training-ameliorates-long-term-alzheimer-s-disease-like-pathological-deficits-by-reducing-nlrp3-inflammasomes-in-pr5-mice
#17
Qing-Guo Ren, Wei-Gang Gong, Hong Zhou, Hao Shu, Yan-Juan Wang, Zhi-Jun Zhang
Recent studies have suggested that cognitive training could delay memory loss in Alzheimer's disease (AD). However, whether and how cognitive training produces long-term benefits remains unclear. Here, 10-month-old PR5 mice were spatially trained in a water maze for 4 consecutive weeks. The novel object recognition test (NORT), Western blots, Golgi staining, and ELISA were used to examine behavioral, biochemical, and pathological measures immediately after training and 3 months later. Immediately after training, we found that spatial training significantly improved cognitive performance; reduced tau neuropathology; increased the expression level of synaptophysin, PSD93, and PSD95 in the hippocampus; and increased the number of dendritic spines in PR5 mice...
December 17, 2018: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/30542906/gene-therapy-for-neurodegenerative-diseases
#18
REVIEW
Vivek Sudhakar, R Mark Richardson
Gene therapy has the potential to provide therapeutic benefit to millions of people with neurodegenerative diseases through several means, including direct correction of pathogenic mechanisms, neuroprotection, neurorestoration, and symptom control. Therapeutic efficacy is therefore dependent on knowledge of the disease pathogenesis and the required temporal and spatial specificity of gene expression. An additional critical challenge is achieving the most complete transduction of the target structure while avoiding leakage into neighboring regions or perivascular spaces...
December 12, 2018: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/30542905/the-role-of-the-peripheral-nerve-surgeon-in-the-treatment-of-pain
#19
REVIEW
Louis H Poppler, Susan E Mackinnon
Pain is a frequent cause of physician visits. Many physicians find these patients challenging because they often have complicated histories, emotional comorbidities, confusing examinations, difficult problems to fix, and the possibility of factitious complaints for attention or narcotic pain medications. As a result, many patients are lumped into the category of chronic, centralized pain and relegated to pain management. However, recent literature suggests that surgical management of carefully diagnosed generators of pain can greatly reduce patients' pain and narcotic requirements...
December 12, 2018: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/30542904/tractography-for-surgical-neuro-oncology-planning-towards-a-gold-standard
#20
REVIEW
Sandip S Panesar, Kumar Abhinav, Fang-Cheng Yeh, Timothée Jacquesson, Malie Collins, Juan Fernandez-Miranda
Magnetic resonance imaging tractography permits in vivo visualization of white matter structures. Aside from its academic value, tractography has been proven particularly useful to neurosurgeons for preoperative planning. Preoperative tractography permits both qualitative and quantitative analyses of tumor effects upon surrounding white matter, allowing the surgeon to specifically tailor their operative approach. Despite its benefits, there is controversy pertaining to methodology, implementation, and interpretation of results in this context...
December 12, 2018: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
journal
journal
41497
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"